IBRX icon

ImmunityBio

2.47 USD
-0.01
0.40%
At close Apr 17, 4:00 PM EDT
After hours
2.45
-0.02
0.81%
1 day
-0.40%
5 days
-0.40%
1 month
-15.12%
3 months
-15.99%
6 months
-28.20%
Year to date
-3.89%
1 year
-52.86%
5 years
-25.15%
10 years
-92.87%
 

About: ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Employees: 680

0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

120% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 20

71% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 41

11% more funds holding

Funds holding: 180 [Q3] → 199 (+19) [Q4]

1.45% more ownership

Funds ownership: 9.86% [Q3] → 11.32% (+1.45%) [Q4]

17% less call options, than puts

Call options by funds: $8.21M | Put options by funds: $9.86M

17% less capital invested

Capital invested by funds: $256M [Q3] → $212M (-$43.8M) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$8
224%
upside
Avg. target
$15.33
521%
upside
High target
$30
1,115%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Andres Maldonado
16% 1-year accuracy
8 / 51 met price target
224%upside
$8
Buy
Reiterated
16 Apr 2025
D. Boral Capital
Jason Kolbert
21% 1-year accuracy
74 / 353 met price target
1,115%upside
$30
Buy
Maintained
15 Apr 2025
HC Wainwright & Co.
Andrew Fein
27% 1-year accuracy
95 / 352 met price target
224%upside
$8
Buy
Initiated
6 Mar 2025

Financial journalist opinion

Based on 6 articles about IBRX published over the past 30 days

Neutral
Business Wire
5 days ago
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for BCG-unresponsive NMIBC in papillary disease and an EAP for ANKTIVA® (nogapendekin alfa inbakicept-pmln) for the treatment of lymphopenia. Supplemental Biologics License Application (sBLA): In Q1, ImmunityBio completed the submission to the FDA of an sBLA for the use of ANKTIVA plus BCG in BCG-unrespon.
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
Neutral
Business Wire
1 week ago
ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into a securities purchase agreement for a registered direct offering with a single institutional investor, providing for the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of Immu.
ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor
Neutral
PRNewsWire
1 week ago
Pomerantz LLP and Holzer & Holzer, LLC Announce Pendency and Proposed Settlement of Class Action Involving Purchases of ImmunityBio, Inc. Securities
SAN DIEGO , April 7, 2025 /PRNewswire/ -- UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA IN RE IMMUNITYBIO, INC.                                             SECURITIES LITIGATION No.
Pomerantz LLP and Holzer & Holzer, LLC Announce Pendency and Proposed Settlement of Class Action Involving Purchases of ImmunityBio, Inc. Securities
Neutral
Business Wire
1 week ago
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced details about its Investor Day program to be held on Tuesday, April 15, 2025, at 10:00 am PDT. The program will include an in-depth update on the company's business operations, U.S. and global regulatory advances of its clinical-stage products, with fireside chats hosted by Dr. Patrick Soon-Shiong and key opinion leaders involved in the company's research programs. The discus.
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch
Positive
Seeking Alpha
2 weeks ago
ImmunityBio: Taking Care Of Business
ImmunityBio, Inc.'s recent progress on Anktiva and rBCG, including FDA submissions and collaborations, positions the company for significant revenue growth despite current financial challenges. The severe BCG shortage impacts Anktiva's growth, but ImmunityBio's rBCG efforts could fill the supply gap and potentially redefine NMIBC treatment. Despite strong commercial momentum, ImmunityBio's financial health remains a concern, with a quarterly cash burn rate of $104.4M and a cash runway of less than four months.
ImmunityBio: Taking Care Of Business
Neutral
Business Wire
3 weeks ago
ImmunityBio to Host Investor Day
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, invites current and prospective investors to its Investor Day program to be held on Tuesday, April 15, 2025, at 10:00 am PDT. The program will include an in-depth update on the company's business operations and recent R&D advancements. Key timelines for catalysts of product candidates will be presented, along with a discussion of ongoing clinical trials. “ImmunityBio commenced 2025 with.
ImmunityBio to Host Investor Day
Neutral
Business Wire
1 month ago
ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation's largest independent providers of urology and related specialty services, is one of the first providers to participate in ImmunityBio's Expanded Access Program (EAP) for recombinant Bacillus Calmette-Guérin (rBCG) to address the current shortage of TICE® BCG in the U.S. “The shortage of BCG has real consequences, especially in many ru.
ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
Negative
Seeking Alpha
1 month ago
ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum
ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash burn, limited cash runway, and substantial debt, despite backing from billionaire founder Dr. Patrick Soon-Shiong. Anktiva's market adoption is uncertain beyond NMIBC, with potential hurdles in expanding to other indications like NSCLC, ovarian cancer, and TNBC.
ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum
Negative
Zacks Investment Research
1 month ago
ImmunityBio (IBRX) Reports Q4 Loss, Misses Revenue Estimates
ImmunityBio (IBRX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.19 per share a year ago.
ImmunityBio (IBRX) Reports Q4 Loss, Misses Revenue Estimates
Neutral
Business Wire
1 month ago
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-code (J9028) in January 2025, as well as its financial results for the fourth-quarter and full year ended December 31, 2024. With the issuance of the permanent J-code in January 2025, ImmunityBio has seen increased sales momentum supporting a trend of increases month-over-month as well as quarter-over-quarter,.
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
Charts implemented using Lightweight Charts™